FDA Archives - Page 215 of 220

4 minute read

FDA
News

COSELA (Trilaciclib Hydrochloride For Injection) Now Approved In China To Decrease The Incidence Of Chemotherapy-Induced Myelosuppression In Patients With Extensive-Stage Small Cell Lung Cancer

July 13, 10:17 AM

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) RESEARCH

GTHX

1 minute read

NeuroSense Therapeutics Shares Move Sharply Higher; Traders Circulate Presentation Slide Saying PrimeC ‘Significantly Alters Key ALS Biomarkers’

By Benzinga Newsdesk

July 13, 9:24 AM

https://docs.publicnow.com/viewDoc?hash_primary=E643C899EAD84D83637D61C470FEB3BAE9F37120

NRSN

1 minute read

FDA
News

Health Canada Clears Cutera’s AviClear

By Benzinga Newsdesk

July 13, 9:07 AM

https://www.businesswire.com/news/home/20220713005256/en/

CUTR

3 minute read

The Daily Biotech Pulse: AstraZeneca’s COVID-19 Vaccine As Effective As mRNA Shots, Humanigen’s Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth’s Alzheimer’s Program

By Vandana Singh

July 13, 9:00 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AGIO

2 minute read

Pluristem Reports Topline Results From Its Phase III Study Of Muscle Regeneration Following Hip Fracture Surgery

By Benzinga Newsdesk

July 13, 6:02 AM

Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) (“Pluristem” or the “Company”), a leading biotechnology company, today announced topline results from its multinational double-blind,

PSTI

1 minute read

Atara Biotherapeutics Announces Completion Of The ATA188 Phase 2 EMBOLD Study Interim Analysis In Patients With Progressive MS

By Benzinga Newsdesk

July 12, 4:31 PM

Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment IDSMC Did Not Identify Any Safety Concerns Phase 2 Study Target Enrollment Achieved; Final Data

ATRA

7 minute read

FDA
News

Vaxcyte Completes Enrollment Of Phase 2 Portion Of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability And Immunogenicity Of VAX-24 In Adults

By Benzinga Newsdesk

July 12, 4:06 PM

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- Company Expects to Announce Topline Results from the

PCVX

1 minute read

Synlogic Granted U.S. Patent Titled ‘BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION (INCLUDING BUT NOT LIMITED TO CELIAC DISEASE, CROHN’S DISEASE, MULTIPLE SCLEROSIS)’

By Benzinga Newsdesk

July 12, 3:43 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11384359&OS=11384359&RS=11384359

SYBX

1 minute read

FDA
News

CDC Says Will No Longer Require Air Passengers Traveling To U.S. To Show Negative Covid-19 Viral Test Or Documentation Of Recovery From Covid-19 Before Boarding Flight

By Benzinga Newsdesk

July 12, 12:14 PM

-Reuters

AZN

3 minute read

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements In Alzheimer’s Disease Mouse Model; Shares Halted On Circuit Breaker

By Benzinga Newsdesk

July 12, 10:26 AM

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease

HOTH